Gene · 1024
Papers2,191
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,121 to 1,140 of 2,191
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Tumor suppressive effects of the pleiotropically acting miR-195 in colorectal cancer cells. | EXCLI J | 2019 | 31217787 | PubTator, text mining | PubMed |
| Protein-Protein Interaction Network Analysis Reveals Several Diseases Highly Associated with Polycystic Ovarian Syndrome. | Int J Mol Sci | 2019 | 31216618 | PubTator, text mining | PubMed |
| The role of circulatory systemic environment in predicting interferon-alpha-induced depression: The neurogenic process as a potential mechanism. | Brain Behav Immun | 2019 | 31207337 | PubTator, text mining | PubMed |
| Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway. | Cancer Med | 2019 | 31207099 | PubTator, text mining | PubMed |
| Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology. | PLoS Comput Biol | 2019 | 31206508 | PubTator, text mining | PubMed |
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). | J Thorac Oncol | 2019 | 31195180 | PubTator, text mining | PubMed |
| Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway. | J Transl Med | 2019 | 31171023 | PubTator, text mining | PubMed |
| Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. | Genet Med | 2019 | 31155615 | PubTator, text mining | PubMed |
| Transcriptomic analyses reveal the molecular mechanisms of schisandrin B alleviates CCl4-induced liver fibrosis in rats by RNA-sequencing. | Chem Biol Interact | 2019 | 31150632 | PubTator, text mining | PubMed |
| Computational Simulations Identify Pyrrolidine-2,3-Dione Derivatives as Novel Inhibitors of Cdk5/p25 Complex to Attenuate Alzheimer's Pathology. | J Clin Med | 2019 | 31137734 | PubTator, text mining | PubMed |
| Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. | Sci Adv | 2019 | 31131319 | PubTator, text mining | PubMed |
| Loss of CDKN2A and CDKN2B expression is associated with disease recurrence in oral cancer. | J Oral Maxillofac Pathol | 2019 | 31110422 | PubTator, text mining | PubMed |
| NPR1 Promotes Its Own and Target Gene Expression in Plant Defense by Recruiting CDK8. | Plant Physiol | 2019 | 31110139 | PubTator, text mining | PubMed |
| Targeting Super-Enhancers as a Therapeutic Strategy for Cancer Treatment. | Front Pharmacol | 2019 | 31105558 | PubTator, text mining | PubMed |
| Macro Histone Variants: Emerging Rheostats of Gastrointestinal Cancers. | Cancers (Basel) | 2019 | 31096699 | PubTator, text mining | PubMed |
| The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab. | J Cell Biochem | 2019 | 31087707 | PubTator, text mining | PubMed |
| Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation. | Cancers (Basel) | 2019 | 31075839 | PubTator, text mining | PubMed |
| Perturbing Enhancer Activity in Cancer Therapy. | Cancers (Basel) | 2019 | 31067678 | PubTator, text mining | PubMed |
| BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature. | BMC Med Genet | 2019 | 31064327 | PubTator, text mining | PubMed |
| Increasing Upstream Chromatin Long-Range Interactions May Favor Induction of Circular RNAs in LysoPC-Activated Human Aortic Endothelial Cells. | Front Physiol | 2019 | 31057422 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1024/papers?page=57